Analysts Maintain PHC Holdings Valuation as Board Reviews Eversense Transfer and Discount Rate Falls

Analysts have reaffirmed the price target for PHC Holdings at ¥1,208.57. This reflects stable expectations given unchanged fair value estimates and generally consistent assumptions behind the company's key financial metrics.

Analysts have slightly lowered their price target for PHC Holdings from ¥1,208.57 to ¥1,208.57, primarily citing a modestly reduced discount rate as the main reason for this minor adjustment. What's in the News PHC Holdings Corporation will hold a Board Meeting on September 4, 2025 to consider approving the transfer of the commercial operation of the Eversense Continuous Glucose Monitoring System to Senseonics Holdings, Inc.

Analysts have raised their price target for PHC Holdings from ¥1,045 to ¥1,209. This change reflects expectations of modest improvements in profit margins, even though revenue growth forecasts are slightly lower and a higher discount rate has been applied.

Despite a slight decline in consensus revenue growth expectations, an improved net profit margin has driven a higher consensus analyst price target for PHC Holdings, which has increased from ¥978 to ¥1045. What's in the News Board approved signing a memorandum of understanding to transfer the commercial operation of Eversense Continuous Glucose Monitoring System from subsidiary Ascensia Diabetes CareHoldings AG to Senseonics Holdings, Inc.